Improving Memory in Patients With Multiple Sclerosis

• Status: Withdrawn
• Trial end date: 2002-08-01
• Target enrollment: 0
• Participant gender: All

Summary

People with multiple sclerosis (MS) suffer from cognitive and other brain problems. This study will examine the effectiveness of the drug donepezil and of sugar water for enhancing memory in individuals with MS. Donepezil (also known as Aricept) has been FDA approved for improving memory and learning in individuals with Alzheimer's disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
• Collaborator: U.S. Department of Education
• Treatments: Donepezil

Criteria

Inclusion Criteria

• MS as defined by the Poser criteria

• Expanded Disability Status Scale (EDSS) score of 0 to 6.5

• Stable neurologic function for at least 30 days prior to study entry

• Agree to continue all current medications for study duration

• Rey Auditory Verbal Learning Test score in low normal range or below

• Mini-mental status exam score of 26 or higher

• Montgomery-Asberg Depression Scale scaled score of 14 or lower

• Fluent in English

Exclusion Criteria

• Use of anticholinergic or benzodiazepine medication

• Change in dosage of medications judged to have the potential to impact cognitive function (e.g., antispasticity medications) within 2 weeks of study entry

• Current alcohol or substance abuse

• History of neurological or major medical problem that has a known effect on cognitive functioning

• History of noncompliance

• Visual or upper extremity impairment which precludes ability to participate in cognitive assessment